Clinical Trials in Dongguan, China
2 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 2
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Solid Tumors
DualityBio Inc.492 enrolled37 locationsNCT06953089
Recruiting
Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China
AstraZeneca200 enrolled26 locationsNCT07161388
Recruiting
Phase 3
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Breast Cancer
AstraZeneca300 enrolled82 locationsNCT06635447
Recruiting
Phase 1
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
Breast CancerLocally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.26 enrolled7 locationsNCT05461768
Recruiting
Not Applicable
Lobectomy-First vs. Lymphadenectomy-First for Operable NSCLC (LOFTY)
Sun Yat-sen University620 enrolled26 locationsNCT06577792
Recruiting
Phase 2
Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
Breast Cancer
Sun Yat-sen University192 enrolled5 locationsNCT06768931
Recruiting
Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns
Metastatic Breast Cancer
Sun Yat-sen University800 enrolled23 locationsNCT06551220
Recruiting
Phase 2
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Non-small Cell Lung Cancer
Sun Yat-sen University280 enrolled26 locationsNCT05334277
Recruiting
Phase 3
Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University688 enrolled17 locationsNCT02062489